Corana vaccine

Two-dose COVID-19 vaccination regimens do not elicit adequate neutralising antibodies against the Omicron coronavirus variant, according to British researchers, implying that higher infections in persons who have been infected or vaccinated are expected. On Monday, researchers from the University of Oxford revealed the findings of an unpublished investigation in which they analysed blood samples from participants in a big trial who were given dosages from AstraZeneca-Oxford or Pfizer-BioNTech.

The findings came only one day after British Prime Minister Boris Johnson warned that two vaccination doses would not be enough to prevent the Omicron form from spreading.

Four coronavirus disease 2019 (COVID-19) vaccines manufactured by Pfizer/BioNTech, Moderna, AstraZeneca, and Janssen-Cilag have gained emergency use authorisation (EUA) in France, and a quick vaccination campaign to safeguard civilians has begun. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that produced the COVID-19 pandemic has been described as highly transmissible, virulent, and with a high fatality rate.

In January 2021, elderly people and frontline workers, who were at a high risk of COVID-19 infection, were prioritized for SARS-CoV-2 vaccination. However, gradually, it was extended to younger age groups down to 12 years of age. Although the vaccination coverage rapidly increased, it slackened significantly by the end of the summer.

The need for booster vaccines

The emergence of SARS-CoV-2 variants occurred due to mutations. Scientists have categorized the variants as variants of concern (VOC) and variants of interest (VOI). In February 2021, SARS-CoV-2 Alpha VOC became dominant in metropolitan France, which was replaced by Delta VOC. At present, the Delta variant has become the dominant circulating strain and has been characterized as more virulent and transmissible than the original SARS-CoV-2 strain. It can also evade the immune response induced by vaccines or natural infection. Many studies have reported that the efficacy of the available COVID-19 vaccines has been lower in the case of the Delta strain compared to other SARS-CoV-2 variants. Previous studies have also shown waning of immune protection, elicited via vaccines or natural infection, with time. Owing to these reasons many countries have recommended COVID-19 booster shots for already vaccinated individuals.

France’s government had initially recommended COVID-19 booster dose for people who are above 65years as well as other vulnerable groups, six months after completion of the two-dose vaccination regime. However, more recently, the eligibility for the booster dose has been extended to all adults.

Effectiveness

In Europe, the number of COVID-19 cases has again started to increase. In this scenario, along with constraints in the global supply of vaccines, researchers believe it is extremely important to evaluate the effectiveness of booster vaccination campaigns. Researchers have used a deterministic, age-structured, compartmental model for this assessment. In this model, they fitted data that were associated with hospital admission and deaths. The authors validated sero-prevalence data in France to determine the effect of primary and booster vaccination strategies on morbidity and mortality.

This study is available on the medRxiv* preprint server. In this study, scientists made two assumptions, i.e., waning of immunity and enhanced virus transmissibility in winter.

Researchers compared vaccination strategies based on prioritization between primary vaccination and booster vaccination. This study revealed that the most beneficial strategy was to distribute all available doses of COVID-19 vaccines predominantly for primary vaccinations and the remaining doses for boosters. This result also emphasizes the fact that higher population immunity plays a greater part in protecting vulnerable groups than in protecting individuals.

The current study reported that in the scenario where if the effectiveness of vaccines were to be decreased among all age groups, the most effective approach to reduce hospitalization and death due to COVID-19 would be to provide booster vaccines for the 30-49 age group. In another scenario, where if the effectiveness of the vaccine were to be reduced for individuals aged 65 years or above, a different boosting vaccination could result in varying outcomes, in terms of, hospitalization and mortality. Therefore, this study suggested two mechanisms based on which healthcare policymakers could decide on which group to target for booster vaccination.

Researchers suggested that the decision must be made on the basis of immunization of vulnerable groups who are prone to severe infection and those with a high risk of transmission. The latter group will help reduce transmission of infection and, thereby, protect the population from further infection. Therefore, an optimal booster vaccination strategy would be based on protecting the vulnerable group as well as the population at large by inhibiting viral transmission. Researchers assumed that a recovered individual would not be reinfected again. Although some studies have reported on the breakthrough infection, not much evidence is available on the risk of re-infection after having recovered from COVID-19.

Conclusion

The model presented in this study helped determine the optimal vaccination strategy related to the primary and booster vaccination approach. Although this study has drawn a conclusion based on the data from metropolitan France, the authors believe that the observations would hold true for other countries as well. The emergence of the Omicron variant has indicated the importance of vaccination coverage throughout the world. Rapid global vaccination will help contain the COVID-19 pandemic soon.

MANILA, Nov 17 (Reuters) – Philippine President Rodrigo Duterte has declared a state of emergency in the The Philippines has approved the emergency use of a COVID-19 vaccine by Novavax Inc (NVAX.O), its food and drug administration chairman said on Wednesday, making it the Southeast Asian country’s eighth vaccine approval.

The nanoparticle vaccine, known as Covovax, will be developed by Serum Institute of India and is licenced for use on individuals 18 and older, according to the agency’s chief Rolando Enrique Domingo during a press conference.

Covovax, which had efficacy of 89.7% in clinical trials, will be administered in two doses not less than 21 days apart, Domingo added.

The Philippines has inoculated more than a quarter of its 110 million population.

Data reveal that for the first time since the start of India’s immunisation campaign, the number of persons fully immunised against Covid-19 has overtaken those who are just partially vaccinated.

The development follows many weeks of second dose administration outpacing that of first doses, a pattern that became quite obvious in October and November when vaccination coverage surpassed 80 percent of the eligible population (at least one shot), a level at which experts expect it to reach a ceiling.

As of Tuesday night, of the 755.4 million people who have received at least one shot of the Covid-19 vaccine in India, 380.7 million people are fully vaccinated (have received both shots) and another 374.7 million have received only one shot, according to data from the CoWIN dashboard. When seen alongside India’s estimated population of 940 million adults, this means that 40.3% of the country’s adults have been fully vaccinated while another 40.2% have been given a single jab so far.

The mathematical significance of this number is that, in combination with non-pharmaceutical interventions such as masking and social distancing, 40% was the level of exposure (or vaccination) at which herd immunity was expected to set in according to a model created by researchers at the University of Nottingham and the University of Stockholm.